Symbiotec Pharmalab Q2 & H1FY27 Investor Presentation Highlights
Symbiotec Pharmalab's Q2 FY27 consolidated revenue rose 43% YoY to ₹280 crore, with PAT up 169% YoY to ₹52 crore. H1FY27 revenue grew 25% to ₹498 crore, and PAT increased 34% to ₹66 crore. The company signed a US DCV distribution agreement, recognizing ₹53 crore revenue. A 10-year take-or-pay CDMO agreement is in advanced stages.
The announcement details significant financial performance improvements and strategic advancements in key growth areas (Complex Injectables and CDMO). These developments are expected to drive future revenue and profitability, impacting the company's valuation and investor perception.
The company reported strong year-on-year growth in revenue and profit for both the quarter and half-year. Positive developments in new business segments like Complex Injectables and CDMO, including new agreements and revenue recognition, contribute to a positive outlook.
Symbiotec Pharmalab Limited has released its Investor Presentation for the quarter and half-year ended September 30, 2026.
The presentation details performance highlights, management commentary, and key business updates across its API, Complex Injectables, and CDMO segments.
In the API business, sales grew steadily by 11% in H1FY27, with both Rau and Pithampur plants receiving EU GMP certification after successful audits. The company also received EIR for USFDA audits at both facilities.
For Complex Injectables, a licensing agreement for the distribution of two DCV products in the US was signed, with partial revenue of ₹53 crore recognized in Q2 FY27. The first molecule ANDA for DCV has been filed and accepted by USFDA, with the second ANDA filing scheduled for Q4 FY27.
The CDMO business saw a 10-year take-or-pay agreement with a US-based Alternate Protein player and a similar agreement in advanced stages with a Europe-based company. A 5-year take-or-pay agreement is also in place for Insulin Drug Substance, with regulatory approval filing expected in Q4 FY27 / Q1 FY28.
Financial highlights for Q2 FY27 show a consolidated revenue of ₹280 crore (up 43% YoY) and consolidated PAT of ₹52 crore (up 169% YoY). For H1FY27, consolidated revenue was ₹498 crore (up 25% YoY) and consolidated PAT was ₹66 crore (up 34% YoY).
Capital expenditure as of September 30, 2026, stood at ₹1,509 crore, with an estimated total gross capex of ₹1,672 crore by the end of FY27. Approximately 61% of the capex is allocated to new businesses expected to generate revenue in the next 6-12 months.
What to do with a filing like this
Symbiotec Pharmalab Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.